Paris, March 27, 2012 - Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases announces today the successful closing of a EUR 1.45 million additional private placement to institutional investors. Following the success of the previous placement of EUR 1.85 million (cf Hybrigenics press release of March 13, 2012) and its favorable welcome by a receptive stock market, excess demand has been fulfilled in this second round of placement. This additional fund-raising will be used, to a large extent, for the scale-up of the chemical manufacturing of inecalcitol that would be needed for further clinical studies with potential pharmaceutical partners.
A total of 1,298,513 new shares have been issued in a private placement at the price of EUR 1.12 each to several qualified investors based upon the delegation of powers approved by the 12th resolution of the Shareholder’s Meeting held on June 25, 2010 and following an accelerated book building procedure according to paragraph II of article L.411-2 of the French Financial and Monetary Code. The new shares represent 8.1% of Hybrigenics’ capital before the transaction and 7.5% after. As in the previous placement, their price represents a discount of 20% on the mean of the volume-weighted average prices of the last five trading days prior to the closing of this transaction. In total, the two placements amount to EUR 3.3 million and 2,948,513 new shares. Bryan Garnier & Co was the exclusive placement agent and book runner.
“The success of these two financial operations has enabled Hybrigenics to strengthen its shareholder base with nine new institutional investors whose aim is to support the Company in its growth”, said Guillaume Floch, Hybrigenics’ CFO.
About Hybrigenics
Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSEEuronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.
Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol is currently being studied in a clinical trial for the treatment of moderate-to-severe psoriasis. Oral inecalcitol is also planned to be tested in chronic lymphocytic leukemia patients. Oral inecalcitol has already shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication.
Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.
Hybrigenics Services SAS, a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.
HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris
ISIN: FR0004153930
Ticker: ALHYG
Hybrigenics
Rémi Delansorne
CEO
Tel.: +33 (0)1 58 10 38 00
vairfgbef@uloevtravpf.pbz
NewCap.
Financial communication
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
uloevtravpf@arjpnc.se
« back to overview